The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.00
Bid: 308.00
Ask: 308.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.162%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 306.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

25 Oct 2019 07:00

RNS Number : 0931R
Synthomer PLC
25 October 2019
 

 

October 25th 2019

 

Synthomer plc

Q3 Trading Update

Continued challenges in European SBR market; Revised FY outlook

 

Synthomer plc ("Synthomer" or "the Group") today issues a trading update for the third quarter ("Q3") ended September 30th 2019.

 

Trading

 

The growing weakness in the global economy has created a more challenging backdrop for the Chemical industry. Depressed European industrial activity combined with increased political and economic uncertainties have resulted in an overall slower trading environment throughout Q3.

 

Performance Elastomers

 

In this environment, Nitrile Butadiene Latex (NBR) had another positive quarter with continued growth supported by the additional 90 ktes of capacity introduced during Q4 2018. NBR volumes increased further during Q3 with year-to-date unit margins remaining stable.

 

In SBR, the Group highlighted challenging conditions in Europe at its H1 results in August. Conditions have not improved during Q3 and the Group's Paper segment has also continued to remain particularly weak. Accordingly, management now expect SBR volumes to be approximately 10% behind 2018 and unit margins to also be similarly lower than last year. A review of network utilisation is currently underway and an update on asset re-purposing and cost base will be provided in conjunction with the Full Year results in March 2020.

 

Functional Solutions

 

Notwithstanding the impact of tough market conditions, overall performance was in line with the first nine months of 2018, with lower volumes offset by higher unit margins. The Group expects to see the benefits of additional capacity at Worms (Germany) and Roebuck (USA) continue to come through in line with the investment case.

 

Industrial Specialities

 

Industrial Specialities continued to trade in-line with management expectations. Volumes and margins were broadly flat with the first nine months of 2018.

 

Financial position

 

At 30 September 2019, the Group remained conservatively levered with net debt/EBITDA, excluding the net proceeds of the rights issue, of 1.4x (30 September 2018: 1.4x).

 

Proposed acquisition of Omnova Solutions Inc.

 

Following approval by both sets of shareholders and competition clearance in the US, the transaction remains subject only to regulatory approval from the European and Turkish competition authorities, and the Group continues to target completion in late 2019.

 

There has been no material change to the expected de-leveraging profile of the Enlarged Group as announced at the time of the transaction.

 

Management remain confident of delivering a swift integration and synergies during 2020.

 

2019 Outlook

 

Whilst Synthomer continues to benefit from its strong product portfolio, end market diversification and geographic presence, the slower trading environment is expected to continue through the remainder of the year and into 2020, particularly in Europe.

 

Whilst Functional Solutions and Industrial Specialities are now expected to be in-line with the prior year, with NBR ahead of 2018, results for the Full Year will be adversely impacted by the increased weakness in the European SBR business.

 

If the current weakness in macroeconomic conditions persist through Q4, excluding any impact from the potential acquisition of OMNOVA, the Board expects underlying profit before tax for FY 2019 to be approximately 10% below 2018 and accordingly current consensus expectations*.

 

- Ends -

 

* Teneo compiled Company consensus: FY 2019 underlying profit before tax - £135.3m

 

Enquiries:

 

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, Head of Investor Relations

 

Tel: + 44 1279 436211

Charles Armitstead, Teneo

Tel: + 44 7703 330 269

 

The Company will hold a conference call for investors and analysts at 0800 BST today:

Dial in number: 08003589473 PIN: 25297905#

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUSUWRKUARUAA
Date   Source Headline
5th Aug 20217:01 amRNSBoard Update
5th Aug 20217:00 amRNSInterim Results
20th Jul 202112:05 pmRNSSynthomer plc receives Green Economy Mark
19th Jul 20217:00 amRNSTrading Update
14th Jul 202111:02 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSAppointment of Non-Executive Director
6th Jul 202112:37 pmRNSDirector/PDMR Shareholding
25th Jun 202110:01 amRNSFurther re Appointment of Group CEO
23rd Jun 20217:00 amRNSAppointment of Group Chief Executive Officer
18th May 20213:53 pmRNSDirector Declaration
12th May 20212:56 pmRNSDirector Declaration
6th May 20214:17 pmRNSDirector Declaration
6th May 20213:15 pmRNSDirector/PDMR Shareholding
29th Apr 20214:01 pmRNSResult of AGM
21st Apr 20217:00 amRNSQ1 Trading Update
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
30th Mar 202110:56 amRNSAnnual Financial Report
19th Mar 20212:38 pmRNSDirector/PDMR Shareholding
12th Mar 20213:17 pmRNSDirector/PDMR Shareholding
12th Mar 20213:16 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
11th Mar 20219:43 amRNSHolding(s) in Company
4th Mar 202112:43 pmRNSPreliminary results – correction
4th Mar 20217:00 amRNSPreliminary Results year ended 31 December 2020
1st Mar 202112:58 pmRNSHolding(s) in Company
24th Feb 20217:00 amRNSStatement RE: Press Speculation
22nd Feb 20214:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20213:38 pmRNSHolding(s) in Company
14th Jan 20217:00 amRNSPre-Close Trading Update and Board Update
12th Jan 20219:36 amRNSHolding(s) in Company
6th Jan 20219:10 amRNSDirector Declaration
4th Jan 202110:09 amRNSDirector Declaration
23rd Dec 20204:54 pmRNSDirector/PDMR Shareholding
17th Dec 20207:00 amRNSAppointment of New Chair
18th Nov 20207:00 amRNSInvestor Seminar
17th Nov 20201:34 pmRNSDirector/PDMR Shareholding
16th Oct 202010:33 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSQ3 Trading Update
7th Oct 20209:20 amRNSHolding(s) in Company
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.